Androgen Receptor Variant–Driven Prostate Cancer II: Advances in Laboratory Investigations

BACKGROUND: The androgen receptor (AR) is a key prostate cancer drug target. Suppression of AR signaling mediated by the full-length AR (AR-FL) is the therapeutic goal of all existing AR-directed therapies. AR-targeting agents impart therapeutic benefit, but lead to AR aberrations that underlie dise...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Changxue, Brown, Landon, Antonarakis, Emmanuel S., Armstrong, Andrew J., Luo, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725416/
https://www.ncbi.nlm.nih.gov/pubmed/32139878
http://dx.doi.org/10.1038/s41391-020-0217-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725416/
https://www.ncbi.nlm.nih.gov/pubmed/32139878
http://dx.doi.org/10.1038/s41391-020-0217-3

Ejemplares similares